PubMed

Pegvisomant-induced lipohypertrophy: report of a case with histopathology.

Marazuela M, Daudén E, Ocón E, Moure D, Nattero L.

Ann Intern Med. 2007 Nov 20;147(10):741-3. No abstract available. PMID: 18025453 [PubMed - indexed for MEDLINE]Related articlesFree article

Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant.

Maffei P, Martini C, Pagano C, Sicolo N, Corbetti F.

Ann Intern Med. 2006 Aug 15;145(4):310-2. No abstract available. PMID: 16908925 [PubMed - indexed for MEDLINE]Related articlesFree article

Lipodystrophy in patients with acromegaly receiving pegvisomant.

Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, Melmed S.

J Clin Endocrinol Metab. 2008 Sep;93(9):3515-8. Epub 2008 Jul 8.PMID: 18611977 [PubMed - indexed for MEDLINE]Related articlesFree article

Subcutaneous lipoatrophy induced by long-term pegvisomant administration.

Salvatore C, Giovanni R, Vittorio C, Claudio S, Patrizia CS.

Clin Endocrinol (Oxf). 2009 Apr;70(4):655-6. Epub 2008 Sep 2. No abstract available. PMID: 18771567 [PubMed - indexed for MEDLINE]Related articles

Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly.

Jehle S, Reyes CM, Sundeen RE, Freda PU.

J Clin Endocrinol Metab. 2005 Mar;90(3):1588-93. Epub 2004 Dec 7.PMID: 15585549 [PubMed - indexed for MEDLINE]Related articlesFree article

[Growth hormone-receptor antagonist pegvisomant]

Herrmann BL, Strasburger CJ.

Dtsch Med Wochenschr. 2004 Oct 29;129(44):2356-8. German. No abstract available. PMID: 15497105 [PubMed - indexed for MEDLINE]Related articles

Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis.

Biering H, Saller B, Bauditz J, Pirlich M, Rudolph B, Johne A, Buchfelder M, Mann K, Droste M, Schreiber I, Lochs H, Strasburger CJ; German pegvisomant investigators.

Eur J Endocrinol. 2006 Feb;154(2):213-20.PMID: 16452533 [PubMed - indexed for MEDLINE]Related articlesFree article

[Pegvisomant decreases growth hormone to nothing]

[No authors listed]

Krankenpfl J. 2004;42(1-2):16-7. German. No abstract available. PMID: 15116768 [PubMed - indexed for MEDLINE]Related articles

Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy.

Frohman LA, Bonert V.

Pituitary. 2007;10(3):283-9.PMID: 17534717 [PubMed - indexed for MEDLINE]Related articles

Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.

Jawiarczyk A, Kałuzny M, Bolanowski M, Bednarek-Tupikowska G.

Neuro Endocrinol Lett. 2008 Aug;29(4):571-6.PMID: 18766168 [PubMed - indexed for MEDLINE]Related articles

[Localized lipohypertrophy during growth hormone therapy]

Mersebach H, Feldt-Rasmussen UF.

Ugeskr Laeger. 2002 Apr 1;164(14):1930-2. Danish. PMID: 11957429 [PubMed - indexed for MEDLINE]Related articles

[Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly]

Zgliczyński W, Zdunowski P.

Endokrynol Pol. 2007 Sep-Oct;58(5):408-16. Polish. PMID: 18058736 [PubMed - indexed for MEDLINE]Related articles

Insulin-induced lipohypertrophy: report of a case with histopathology.

Fujikura J, Fujimoto M, Yasue S, Noguchi M, Masuzaki H, Hosoda K, Tachibana T, Sugihara H, Nakao K.

Endocr J. 2005 Oct;52(5):623-8.PMID: 16284443 [PubMed - indexed for MEDLINE]Related articlesFree article

Pegvisomant increases intra-abdominal fat in patients with acromegaly: a pilot study.

Plöckinger U, Reuter T.

Eur J Endocrinol. 2008 Apr;158(4):467-71.PMID: 18362292 [PubMed - indexed for MEDLINE]Related articlesFree article

Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials.

Jimenez C, Burman P, Abs R, Clemmons DR, Drake WM, Hutson KR, Messig M, Thorner MO, Trainer PJ, Gagel RF.

Eur J Endocrinol. 2008 Nov;159(5):517-23. Epub 2008 Aug 15.PMID: 18708436 [PubMed - indexed for MEDLINE]Related articlesFree article

Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.

Feenstra J, van Aken MO, de Herder WW, Feelders RA, van der Lely AJ.

Eur J Endocrinol. 2006 Jun;154(6):805-6.PMID: 16728538 [PubMed - indexed for MEDLINE]Related articlesFree article

Growth hormone receptor antagonists.

van der Lely AJ, Kopchick JJ.

Neuroendocrinology. 2006;83(3-4):264-8. Epub 2006 Oct 13. Review.PMID: 17047392 [PubMed - indexed for MEDLINE]Related articles

Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.

De Marinis L, Bianchi A, Fusco A, Cimino V, Mormando M, Tilaro L, Mazziotti G, Pontecorvi A, Giustina A.

Pituitary. 2007;10(3):227-32.PMID: 17484056 [PubMed - indexed for MEDLINE]Related articles

Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly.

Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ.

J Clin Endocrinol Metab. 2007 Dec;92(12):4598-601. Epub 2007 Sep 25.PMID: 17895318 [PubMed - indexed for MEDLINE]Related articlesFree article

The medical treatment of acromegaly.

van der Lely AJ.

Endokrynol Pol. 2007 Jul-Aug;58(4):361-3. Review.PMID: 18058730 [PubMed - indexed for MEDLINE]Related articles